Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding

This retrospective study, utilizing U.S. electronic health record (EHR) data from January 2013 to December 2020, sought to assess whether rivaroxaban and apixaban had similar effectiveness and safety in the treatment of cancer-associated venous thromboembolism (VTE) in patients with a cancer type no...

Descripción completa

Detalles Bibliográficos
Autores principales: Caroti, Kimberly Snow, Becattini, Cecilia, Carrier, Marc, Cohen, Alexander T., Ekbom, Anders, Khorana, Alok A., Lee, Agnes Y.Y., Brescia, Christopher, Abdelgawwad, Khaled, Psaroudakis, George, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Coleman, Craig I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332896/
https://www.ncbi.nlm.nih.gov/pubmed/37435565
http://dx.doi.org/10.1055/s-0043-1770783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332896/
https://www.ncbi.nlm.nih.gov/pubmed/37435565
http://dx.doi.org/10.1055/s-0043-1770783

Ejemplares similares